
Cleocin Injection Clindamycin 150 mg/mL Vial 4 mL x 25/Box (RX)



Clindamycin (brand Cleocin) is a lincosamide antibiotic supplied as Clindamycin Phosphate for injection. Each mL of solution contains 150 mg clindamycin base. It is active against many gram-positive cocci (e.g. Streptococcus pyogenes, Staphylococcus aureus – methicillin-susceptible strains) and anaerobes (e.g. Clostridium perfringens, Fusobacterium, Prevotella, Peptostreptococcus). Clindamycin inhibits protein synthesis by binding the 23S rRNA of the 50S ribosomal subunit, blocking bacterial growth (bacteriostatic). It thus “turns off” infection by stopping bacteria from making proteins needed to live and spread. (It has no activity against most Gram-negative aerobes and not against Enterococcus.)
Cleocin injection is indicated for serious infections caused by susceptible organisms, especially when penicillins/cephalosporins are not an option. It covers:
In practice, clindamycin is reserved for serious infections. The official label emphasizes it should be used only if safer alternatives are inappropriate, due to its toxicity profile. It is not indicated for routine mild infections or viral illnesses; for example it should not be used for routine upper respiratory infections
Cleocin injection is given intravenously or intramuscularly. The standard adult IV dosing is 600–1200 mg per day divided every 6–8 hours for serious infections (doses up to 4800 mg/day have been used in life-threatening cases). For children (≥1 month), 20–40 mg/kg/day in divided doses is typical.
Dilution (IV): Clindamycin vials must be diluted in IV fluid before infusion. Reconstitute each 150 mg vial with sterile water (150 mg/mL) then dilute so the final concentration is ≤18 mg/mL. For example, 600 mg can be diluted in 50 mL (12 mg/mL) and infused over ~20 minutes. The label provides recommended infusion rates (e.g. 300 mg/50 mL over 10 min; 900 mg/100 mL over 30 min). Important: do not push clindamycin undiluted IV. It must be infused slowly—over at least 10–60 minutes as directed —to avoid severe hypotension or cardiac effects. Always flush the IV line before and after with saline.
Intramuscular (IM): If IV access is not available, clindamycin can be injected IM (deep, into a large muscle). IM injection is painful and maximal volume should be 2–3 mL per site. Do not exceed 600 mg in one IM dose. (Thus multiple vials would be given in separate sites if needed.) If using IM, use a long needle into gluteal or thigh muscle.
Renal/Hepatic impairment: No dosage adjustment is needed for kidney disease. In severe liver disease clindamycin levels rise, so use usual doses but monitor liver function (periodic LFTs).
Mixing: Clindamycin IV is compatible with saline or D5W. Check institutional policies for IV admixture. Never mix with drugs that are known to precipitate with it (compatibility charts should be consulted).
Flow rates: Very important – always adhere to the recommended infusion rates. For example, the label caps infusion at 30 mg/min and warns against undiluted IV injection. Pediatric patients should have IV doses infused more slowly to avoid apnea or bradyarrhythmia.
Clindamycin works by halting bacterial protein synthesis. It binds the 23S rRNA of the 50S ribosomal subunit, preventing peptide chain elongation. This stops bacteria from growing (it is generally bacteriostatic). Because it blocks protein synthesis in target bacteria, helpful immune cells can clear the stalled organisms. Resistance can occur (e.g. methylase enzymes that prevent binding), so susceptibility testing is recommended.
Clindamycin covers most anaerobes and Gram-positive cocci. The label lists activity against: Staph aureus (MSSA strains), Strep pneumoniae (penicillin-susceptible), Strep pyogenes (strep throat), and several anaerobes (e.g. C. perfringens, Fusobacterium, Prevotella, Peptostreptococcus species). In practice it is often used for culture-proven or suspected infections by these bugs. However, it does not reliably cover MRSA (only if lab confirms susceptibility) or enterococci. For MRSA or macrolide-resistant strains, a D-zone test must be done because of inducible clindamycin resistance.
Summary: Cleocin 150 mg injection is a potent antibiotic for serious anaerobic and gram-positive infections, especially when first-line drugs can’t be used. It “fights infections” by stopping bacterial protein assembly. Administration requires proper dilution and slow infusion. Nurses and doctors should watch for injection site reactions and especially C. difficile colitis. Inform patients about possible GI upset and emphasize finishing the course. Clindamycin should be reserved for appropriate cases to maximize benefit and minimize risks (resistance, colitis).
Clindamycin (brand Cleocin) is a lincosamide antibiotic supplied as Clindamycin Phosphate for injection. Each mL of solution contains 150 mg clindamycin base. It is active against many gram-positive cocci (e.g. Streptococcus pyogenes, Staphylococcus aureus – methicillin-susceptible strains) and anaerobes (e.g. Clostridium perfringens, Fusobacterium, Prevotella, Peptostreptococcus). Clindamycin inhibits protein synthesis by binding the 23S rRNA of the 50S ribosomal subunit, blocking bacterial growth (bacteriostatic). It thus “turns off” infection by stopping bacteria from making proteins needed to live and spread. (It has no activity against most Gram-negative aerobes and not against Enterococcus.)
Cleocin injection is indicated for serious infections caused by susceptible organisms, especially when penicillins/cephalosporins are not an option. It covers:
In practice, clindamycin is reserved for serious infections. The official label emphasizes it should be used only if safer alternatives are inappropriate, due to its toxicity profile. It is not indicated for routine mild infections or viral illnesses; for example it should not be used for routine upper respiratory infections
Cleocin injection is given intravenously or intramuscularly. The standard adult IV dosing is 600–1200 mg per day divided every 6–8 hours for serious infections (doses up to 4800 mg/day have been used in life-threatening cases). For children (≥1 month), 20–40 mg/kg/day in divided doses is typical.
Dilution (IV): Clindamycin vials must be diluted in IV fluid before infusion. Reconstitute each 150 mg vial with sterile water (150 mg/mL) then dilute so the final concentration is ≤18 mg/mL. For example, 600 mg can be diluted in 50 mL (12 mg/mL) and infused over ~20 minutes. The label provides recommended infusion rates (e.g. 300 mg/50 mL over 10 min; 900 mg/100 mL over 30 min). Important: do not push clindamycin undiluted IV. It must be infused slowly—over at least 10–60 minutes as directed —to avoid severe hypotension or cardiac effects. Always flush the IV line before and after with saline.
Intramuscular (IM): If IV access is not available, clindamycin can be injected IM (deep, into a large muscle). IM injection is painful and maximal volume should be 2–3 mL per site. Do not exceed 600 mg in one IM dose. (Thus multiple vials would be given in separate sites if needed.) If using IM, use a long needle into gluteal or thigh muscle.
Renal/Hepatic impairment: No dosage adjustment is needed for kidney disease. In severe liver disease clindamycin levels rise, so use usual doses but monitor liver function (periodic LFTs).
Mixing: Clindamycin IV is compatible with saline or D5W. Check institutional policies for IV admixture. Never mix with drugs that are known to precipitate with it (compatibility charts should be consulted).
Flow rates: Very important – always adhere to the recommended infusion rates. For example, the label caps infusion at 30 mg/min and warns against undiluted IV injection. Pediatric patients should have IV doses infused more slowly to avoid apnea or bradyarrhythmia.
Clindamycin works by halting bacterial protein synthesis. It binds the 23S rRNA of the 50S ribosomal subunit, preventing peptide chain elongation. This stops bacteria from growing (it is generally bacteriostatic). Because it blocks protein synthesis in target bacteria, helpful immune cells can clear the stalled organisms. Resistance can occur (e.g. methylase enzymes that prevent binding), so susceptibility testing is recommended.
Clindamycin covers most anaerobes and Gram-positive cocci. The label lists activity against: Staph aureus (MSSA strains), Strep pneumoniae (penicillin-susceptible), Strep pyogenes (strep throat), and several anaerobes (e.g. C. perfringens, Fusobacterium, Prevotella, Peptostreptococcus species). In practice it is often used for culture-proven or suspected infections by these bugs. However, it does not reliably cover MRSA (only if lab confirms susceptibility) or enterococci. For MRSA or macrolide-resistant strains, a D-zone test must be done because of inducible clindamycin resistance.
Summary: Cleocin 150 mg injection is a potent antibiotic for serious anaerobic and gram-positive infections, especially when first-line drugs can’t be used. It “fights infections” by stopping bacterial protein assembly. Administration requires proper dilution and slow infusion. Nurses and doctors should watch for injection site reactions and especially C. difficile colitis. Inform patients about possible GI upset and emphasize finishing the course. Clindamycin should be reserved for appropriate cases to maximize benefit and minimize risks (resistance, colitis).
You need an account to add products to your wishlist. Log in or create an account to start saving your favorites.